FR14C0016I2 - Vacccin west nile - Google Patents

Vacccin west nile

Info

Publication number
FR14C0016I2
FR14C0016I2 FR14C0016C FR14C0016C FR14C0016I2 FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2 FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 C FR14C0016 C FR 14C0016C FR 14C0016 I2 FR14C0016 I2 FR 14C0016I2
Authority
FR
France
Prior art keywords
west nile
nile vaccine
vaccine
west
nile
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR14C0016C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zoetis Services LLC
Original Assignee
Zoetis W LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis W LLC filed Critical Zoetis W LLC
Publication of FR14C0016I1 publication Critical patent/FR14C0016I1/fr
Application granted granted Critical
Publication of FR14C0016I2 publication Critical patent/FR14C0016I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR14C0016C 2001-07-27 2014-02-21 Vacccin west nile Active FR14C0016I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30833401P 2001-07-27 2001-07-27
PCT/US2002/023447 WO2003061555A2 (fr) 2001-07-27 2002-07-23 Vacccin west nile

Publications (2)

Publication Number Publication Date
FR14C0016I1 FR14C0016I1 (fr) 2014-03-28
FR14C0016I2 true FR14C0016I2 (fr) 2015-07-24

Family

ID=27613166

Family Applications (1)

Application Number Title Priority Date Filing Date
FR14C0016C Active FR14C0016I2 (fr) 2001-07-27 2014-02-21 Vacccin west nile

Country Status (25)

Country Link
US (8) US7153513B2 (fr)
EP (3) EP2283858A3 (fr)
JP (2) JP4718778B2 (fr)
KR (2) KR20040028952A (fr)
CN (2) CN1935258B (fr)
AU (1) AU2002365244B2 (fr)
BE (1) BE2014C006I2 (fr)
BR (1) BRPI0211492B1 (fr)
CA (1) CA2452545C (fr)
CY (1) CY2014010I2 (fr)
DK (1) DK1427444T3 (fr)
ES (1) ES2435095T3 (fr)
FR (1) FR14C0016I2 (fr)
HK (1) HK1066470A1 (fr)
HR (1) HRP20040195B1 (fr)
HU (2) HU228690B1 (fr)
LU (1) LU92348I2 (fr)
ME (1) ME00491B (fr)
MX (1) MXPA04000680A (fr)
NZ (3) NZ531265A (fr)
PL (2) PL212212B1 (fr)
PT (1) PT1427444E (fr)
RS (1) RS53184B (fr)
WO (1) WO2003061555A2 (fr)
ZA (1) ZA200401596B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7425437B2 (en) * 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
AU2002365244B2 (en) * 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
EP1664786B1 (fr) * 2003-09-09 2014-11-12 Idexx Laboratories, Inc. Detection de l'infection par le virus du nil occidental et vaccination
US7074555B2 (en) * 2004-04-28 2006-07-11 Idexx Laboratories, Inc. Detection of West Nile Virus
FR2870126B1 (fr) 2004-05-17 2009-07-17 Pasteur Institut Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
CA2582534A1 (fr) 2004-09-09 2006-03-16 Research Development Foundation Variants de flavivirus ayant une variation phenotypique et les compositions immunogeniques correspondantes
WO2006107655A2 (fr) * 2005-04-01 2006-10-12 Wyeth Utilisation de vaccin a adn en combinaison avec un vaccin classique pour surmonter l'interference immunogene
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
WO2006120230A2 (fr) 2005-05-12 2006-11-16 Crucell Holland B.V. Molecules de liaison specifiques de cellule hote capables de neutraliser des virus et leurs utilisations
WO2006122964A1 (fr) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methodes de production d'un vaccin contre le virus du nil occidental entier inactive
EP1724338A1 (fr) * 2005-05-19 2006-11-22 Crucell Holland B.V. Méthode de production d'un vaccin de virus de West Nile inactivé complet
AU2006261943B2 (en) 2005-06-24 2010-12-02 Intervet International B.V. Inactivated chimeric vaccines and related methods of use
NZ567809A (en) * 2005-10-19 2012-06-29 Univ Florida Influenza viruses able to infect canids, uses thereof
EP1941033A2 (fr) * 2005-10-20 2008-07-09 Wyeth a Corporation of the State of Delaware Compositions et méthodes pour traiter une virose de la grippe canine
US7767210B2 (en) * 2005-12-14 2010-08-03 The Board Of Regents Of The University Of Oklahoma RNA virus vaccines and methods
HUE027099T2 (hu) * 2006-06-06 2016-08-29 Crucell Holland Bv Humán kötõmolekulák staphylococcus elleni ölõaktivitással és alkalmazásuk
DK2217271T3 (en) * 2007-11-06 2016-06-06 Zoetis Services Llc Avirulent, live vaccine with adjuvant against Mycoplasma hyopneumoniae
WO2009143524A2 (fr) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Vaccins à nanoémulsion
CA2732035A1 (fr) * 2008-07-30 2010-02-04 University Of Kentucky Research Foundation Modele de maladie equine pour maladie neurologique a virus herpetique et utilisations assiociees
SG193821A1 (en) * 2008-08-29 2013-10-30 Boehringer Ingelheim Vetmed West nile virus vaccine
MX2012004133A (es) * 2009-10-07 2012-05-08 Wyeth Llc Composiciones que comprenden adyuvante, macrolido y antigeno proteico y procedimientos de uso de las mismas.
EP2686012B1 (fr) 2011-03-14 2020-12-02 Boehringer Ingelheim Animal Health USA Inc. Vaccin contre la rhinite équine
CN103045544B (zh) * 2011-10-17 2015-01-14 华中农业大学 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用
PT2996719T (pt) * 2013-05-14 2019-09-03 Zoetis Services Llc Composições de vacina inovadoras que compreendem oligonucleótidos imunoestimulantes
MX2016002903A (es) * 2013-09-05 2016-06-06 Zoetis Services Llc Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
WO2017210215A1 (fr) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Vaccin contre le virus zika et procédés d'utilisation
PL70842Y1 (pl) * 2017-08-25 2019-06-28 Gondek Lukasz Kuznia Mocy Urządzenie do regeneracji filtrów cząstek stałych i katalizatorów samochodowych
AR118202A1 (es) 2019-02-27 2021-09-22 Univ Rochester Vacuna multivalente contra la influenza de virus vivos atenuados para la prevención y el control del virus de la influenza equina (eiv) en caballos

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US308334A (en) 1884-11-18 Ladder
US6184024B1 (en) 1988-07-14 2001-02-06 The United States Of America As Represented By The Department Of Health And Human Services Chimeric and/or growth-restricted flaviviruses
US5741696A (en) * 1992-08-07 1998-04-21 Syntro Corporation Recombinant equine herpesviruses
FR2702373B1 (fr) * 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
WO1995030437A1 (fr) * 1994-05-10 1995-11-16 American Home Products Corporation Vaccin vivant modifie, ameliore, contre le virus respiratoire syncytial bovin (vrsb)
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
CA2331368C (fr) 1998-06-04 2009-02-10 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Vaccins a base d'acides nucleiques destines a la prevention de l'infection par flavivirus
AU2002211490A1 (en) 2000-10-04 2002-04-15 The Trustees Of The University Of Pennsylvania Compositions and methods of using capsid protein from flaviviruses and pestiviruses
WO2002068637A2 (fr) 2000-10-20 2002-09-06 Ribozyme Pharmaceuticals, Inc. Traitement a base d'acide nucleique de maladies ou d'etats pathologiques associes a une infection par le virus du nil occidental
US20050048073A1 (en) 2001-02-28 2005-03-03 De Groot Anne S. Methods of determining west nile virus epitopes and method of using the same
AU2002309508A1 (en) * 2001-03-12 2002-09-24 L2 Diagnostics, Llc Compositions and methods comprising west nile virus polypeptides
US20030104008A1 (en) * 2001-04-06 2003-06-05 Loosmore Sheena May Recombinant vaccine against west nile virus
FR2823222B1 (fr) * 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
AU2002365244B2 (en) * 2001-07-27 2007-12-06 Zoetis Services Llc West nile vaccine
WO2004016586A2 (fr) 2002-08-16 2004-02-26 Board Of Regents The University Of Texas System Compositions et methodes associees aux antigenes de domaine iii de la proteine d'enveloppe du flavivirus

Also Published As

Publication number Publication date
BRPI0211492B1 (pt) 2016-06-21
JP4718778B2 (ja) 2011-07-06
FR14C0016I1 (fr) 2014-03-28
MXPA04000680A (es) 2004-04-05
HRP20040195B1 (hr) 2014-07-18
US7648705B2 (en) 2010-01-19
PT1427444E (pt) 2013-11-19
DK1427444T3 (da) 2013-11-04
EP2281572A1 (fr) 2011-02-09
US7445787B2 (en) 2008-11-04
CN1935258A (zh) 2007-03-28
PL368535A1 (en) 2005-04-04
US20070166325A1 (en) 2007-07-19
US20070166802A1 (en) 2007-07-19
PL212212B1 (pl) 2012-08-31
CN1935258B (zh) 2013-04-03
YU8004A (sh) 2006-08-17
HU228690B1 (en) 2013-05-28
AU2002365244B2 (en) 2007-12-06
KR20040028952A (ko) 2004-04-03
ES2435095T3 (es) 2013-12-18
CY2014010I1 (el) 2020-05-29
CY2014010I2 (el) 2024-02-16
US7648706B2 (en) 2010-01-19
US20070166324A1 (en) 2007-07-19
NZ531265A (en) 2008-08-29
EP2283858A3 (fr) 2011-03-23
LU92348I9 (fr) 2019-01-02
BR0211492A (pt) 2004-08-17
US20070231350A1 (en) 2007-10-04
NZ570270A (en) 2010-08-27
CA2452545C (fr) 2015-06-09
ME00491B (fr) 2011-10-10
PL398575A1 (pl) 2012-06-18
KR20090053967A (ko) 2009-05-28
US7153513B2 (en) 2006-12-26
US20070166326A1 (en) 2007-07-19
RS53184B (en) 2014-06-30
HUP0401606A3 (en) 2005-02-28
BE2014C006I2 (fr) 2021-02-04
HRP20040195A2 (en) 2004-08-31
US20030091595A1 (en) 2003-05-15
HUP0401606A2 (hu) 2004-11-29
JP2005515236A (ja) 2005-05-26
CN1535157A (zh) 2004-10-06
HK1066470A1 (en) 2005-03-24
HUS1300055I1 (hu) 2016-08-29
NZ553165A (en) 2008-09-26
PL220846B1 (pl) 2016-01-29
CA2452545A1 (fr) 2003-07-31
WO2003061555A3 (fr) 2004-04-15
WO2003061555A2 (fr) 2003-07-31
EP1427444A4 (fr) 2008-01-02
EP2283858A2 (fr) 2011-02-16
CN1273189C (zh) 2006-09-06
LU92348I2 (fr) 2014-09-22
ZA200401596B (en) 2005-07-27
EP1427444A2 (fr) 2004-06-16
EP1427444B1 (fr) 2013-08-21
US20070231349A1 (en) 2007-10-04
US20070178119A1 (en) 2007-08-02
JP2011057692A (ja) 2011-03-24

Similar Documents

Publication Publication Date Title
FR14C0016I2 (fr) Vacccin west nile
LU93048I2 (fr) Proteq west nile
ATE553775T1 (de) Impstoffzusammesetzung
NO20031483L (no) Vaksine
ATE420159T1 (de) Grippe-impfstoffzusammensetzung
NO20034683D0 (no) Intradermal vaksineinnretning
DE60239828D1 (de) Ür
NO20024172D0 (no) Vaksine
IS7291A (is) Merkt kirni
NO20030823L (no) Vaksiner
NO20026175L (no) Vaksinesammensetning
NO20031705L (no) Vaksiner
IS7547A (is) Ónæmisvaldandi samsetningar
IS7297A (is) Streptococcis Pneumoniae bóluefni
IS7831A (is) Bóluefni
NO20033882D0 (no) Vaksine
DE60328408D1 (de) Impfstoff
NO20051561D0 (no) Vaksine
NO20034165D0 (no) Forankringshylse
DE10290185D2 (de) Tumorvakzine
SE0103470D0 (sv) Hållaranordning
SE0103415D0 (sv) Hållaranordning
SE0100410D0 (sv) Hållaranordning
FI5103U1 (fi) Salibandymaila
NO20011990D0 (no) Kreftvaksine